557 related articles for article (PubMed ID: 22210556)
1. Rituximab for the treatment of IgG4-related disease: lessons from 10 consecutive patients.
Khosroshahi A; Carruthers MN; Deshpande V; Unizony S; Bloch DB; Stone JH
Medicine (Baltimore); 2012 Jan; 91(1):57-66. PubMed ID: 22210556
[TBL] [Abstract][Full Text] [Related]
2. Rituximab therapy leads to rapid decline of serum IgG4 levels and prompt clinical improvement in IgG4-related systemic disease.
Khosroshahi A; Bloch DB; Deshpande V; Stone JH
Arthritis Rheum; 2010 Jun; 62(6):1755-62. PubMed ID: 20191576
[TBL] [Abstract][Full Text] [Related]
3. IgG4-related disease with hypergammaglobulinemic hyperviscosity and retinopathy.
Wong PC; Fung AT; Gerrie AS; Moloney G; Maberley D; Rossman D; White V; Collins D; Coupland R; Chen LY
Eur J Haematol; 2013 Mar; 90(3):250-6. PubMed ID: 23278107
[TBL] [Abstract][Full Text] [Related]
4. IgG4-related systemic disease as a cause of "idiopathic" orbital inflammation, including orbital myositis, and trigeminal nerve involvement.
Wallace ZS; Khosroshahi A; Jakobiec FA; Deshpande V; Hatton MP; Ritter J; Ferry JA; Stone JH
Surv Ophthalmol; 2012; 57(1):26-33. PubMed ID: 22018678
[TBL] [Abstract][Full Text] [Related]
5. Rituximab for IgG4-related disease: a prospective, open-label trial.
Carruthers MN; Topazian MD; Khosroshahi A; Witzig TE; Wallace ZS; Hart PA; Deshpande V; Smyrk TC; Chari S; Stone JH
Ann Rheum Dis; 2015 Jun; 74(6):1171-7. PubMed ID: 25667206
[TBL] [Abstract][Full Text] [Related]
6. Rituximab for idiopathic and IgG4-related retroperitoneal fibrosis.
Wallwork R; Wallace Z; Perugino C; Sharma A; Stone JH
Medicine (Baltimore); 2018 Oct; 97(42):e12631. PubMed ID: 30334947
[TBL] [Abstract][Full Text] [Related]
7. IgG4-related disease: A relatively new concept for clinicians.
Vasaitis L
Eur J Intern Med; 2016 Jan; 27():1-9. PubMed ID: 26481243
[TBL] [Abstract][Full Text] [Related]
8. [IgG4-related disease: patient group characterization and rituximab therapy].
Sedyshev SKh; Vasil'ev VI; Kovrigina AM; Logvinenko OA; Rodionova EB; Safonova TN; Gaĭduk IV; Silin AIu; Komov DV; Nasonov EL
Ter Arkh; 2013; 85(2):48-53. PubMed ID: 23653939
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of rituximab biosimilar (CT-P10) in IgG4-related disease: an observational prospective open-label cohort study.
Della-Torre E; Lanzillotta M; Campochiaro C; Di-Colo G; Mancuso G; Capurso G; Falconi M; Dagna L
Eur J Intern Med; 2021 Feb; 84():63-67. PubMed ID: 33386207
[TBL] [Abstract][Full Text] [Related]
10. IgG4-related disease.
Mahajan VS; Mattoo H; Deshpande V; Pillai SS; Stone JH
Annu Rev Pathol; 2014; 9():315-47. PubMed ID: 24111912
[TBL] [Abstract][Full Text] [Related]
11. [The clinical characteristics of 346 patients with IgG
Zhang PP; Zhao JZ; Wang M; Feng RE; Liu XW; Lai XM; Li XJ; Zeng JG; Shi HJ; Zhu HD; Xue W; Zhang H; Chen YY; Fei LY; Peng XF; Zeng FC; Zhang YM; Zhang W
Zhonghua Nei Ke Za Zhi; 2017 Sep; 56(9):644-649. PubMed ID: 28870031
[No Abstract] [Full Text] [Related]
12. Overlap of IgG4-related Disease and Multicentric Castleman's Disease in a Patient with Skin Lesions.
Mochizuki H; Kato M; Higuchi T; Koyamada R; Arai S; Okada S; Eto H
Intern Med; 2017; 56(9):1095-1099. PubMed ID: 28458319
[TBL] [Abstract][Full Text] [Related]
13. Rituximab in IgG4-related inflammatory disease of the orbit and ocular adnexae.
Lindfield D
Eye (Lond); 2012 Oct; 26(10):1386. PubMed ID: 22814806
[No Abstract] [Full Text] [Related]
14. IgG4 antibodies in autoimmune polyglandular disease and IgG4-related endocrinopathies: pathophysiology and clinical characteristics.
Nambam B; Winter WE; Schatz DA
Curr Opin Pediatr; 2014 Aug; 26(4):493-9. PubMed ID: 24905103
[TBL] [Abstract][Full Text] [Related]
15. Immunoglobulin G4-Related Disease: What an Allergist Should Know.
Carballo I; González-Quintela A; Sopeña B; Vidal C
J Investig Allergol Clin Immunol; 2021 Jun; 31(3):212-227. PubMed ID: 32732179
[TBL] [Abstract][Full Text] [Related]
16. Treatment and outcomes in patients with IgG4-related disease using the IgG4 responder index.
Fernández-Codina A; Pinilla B; Pinal-Fernández I; López C; Fraile-Rodríguez G; Fonseca-Aizpuru E; Carballo I; Brito-Zerón P; Feijóo-Massó C; López-Dupla M; Cid MC; Martínez-Valle F; ; ;
Joint Bone Spine; 2018 Dec; 85(6):721-726. PubMed ID: 29452298
[TBL] [Abstract][Full Text] [Related]
17. Clinical phenotypes of IgG4-related disease reflect different prognostic outcomes.
Lanzillotta M; Campochiaro C; Mancuso G; Ramirez GA; Capurso G; Falconi M; Dagna L; Della-Torre E
Rheumatology (Oxford); 2020 Sep; 59(9):2435-2442. PubMed ID: 32591828
[TBL] [Abstract][Full Text] [Related]
18. Ophthalmic manifestations of IgG4-related disease: single-center experience and literature review.
Wallace ZS; Deshpande V; Stone JH
Semin Arthritis Rheum; 2014 Jun; 43(6):806-17. PubMed ID: 24513111
[TBL] [Abstract][Full Text] [Related]
19. Rituximab for the Treatment of IgG4-Related Tubulointerstitial Nephritis: Case Report and Review of the Literature.
McMahon BA; Novick T; Scheel PJ; Bagnasco S; Atta MG
Medicine (Baltimore); 2015 Aug; 94(32):e1366. PubMed ID: 26266393
[TBL] [Abstract][Full Text] [Related]
20. Successful use of rituximab in a young patient with immunoglobulin G4-related disease and refractory scleritis.
Caso F; Fiocco U; Costa L; Sfriso P; Punzi L; Doria A
Joint Bone Spine; 2014 Mar; 81(2):190-2. PubMed ID: 23932926
[No Abstract] [Full Text] [Related]
[Next] [New Search]
